Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells

J Hematother Stem Cell Res. 2001 Aug;10(4):441-9. doi: 10.1089/15258160152509064.

Abstract

A fundamental problem of antitumor immunity is tumor-induced immunosuppression. Tumor cells often down-regulate expression of co-stimulatory molecules, tumor antigens, and major histocompatibility complex (MHC) molecules on tumor cells, secrete immunosuppressive substance such as transforming growth factor-beta (TGF-beta) or interleukin-4 (IL-4), and induce apoptosis of effector T cells to escape surveillance. A major goal of antitumor or antivirus immunotherapy is to generate long-lived protective T cells that enable killing of target cells. In this review, we discuss the importance of 4-1BB for development or survival of functionally active effector CD8(+) T cells against tumors, virus infection, and allogeneic immune responses and for potential therapeutic application.

Publication types

  • Review

MeSH terms

  • Antigens, CD
  • CD8-Positive T-Lymphocytes / cytology
  • CD8-Positive T-Lymphocytes / drug effects*
  • CD8-Positive T-Lymphocytes / immunology
  • Cell Survival / drug effects
  • Humans
  • Immunotherapy / methods
  • Receptors, Nerve Growth Factor / immunology*
  • Receptors, Nerve Growth Factor / physiology
  • Receptors, Nerve Growth Factor / therapeutic use
  • Receptors, Tumor Necrosis Factor / immunology*
  • Receptors, Tumor Necrosis Factor / physiology
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor Receptor Superfamily, Member 9

Substances

  • Antigens, CD
  • Receptors, Nerve Growth Factor
  • Receptors, Tumor Necrosis Factor
  • TNFRSF9 protein, human
  • Tumor Necrosis Factor Receptor Superfamily, Member 9